Evidence map›Paper›PMID 36759726›Full record

ArticleBritish journal of cancer2023

Prevalence of tumour-infiltrating CD103

Quan Zhou, Yuxi Ou, Xiyu Dai, Xinan Chen, Siqi Wu, Wensun Chen, Mengbo Hu, Chen Yang, Limin Zhang, Haowen Jiang

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. High percentage of bone marrow CD8Blood science (Baltimore, Md.) · 2024
    Article
  5. Spatial features of specific CD103Journal of translational medicine · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Quan Zhou *Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Yuxi Ou *Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Xiyu Dai *Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Xinan Chen *Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Siqi WuDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Wensun ChenDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Mengbo HuDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-7625-2026
Chen YangDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China. yangc_huashan@163.com.ORCID http://orcid.org/0000-0001-6011-4067
Limin ZhangDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China. zhalim@fudan.edu.cn.ORCID http://orcid.org/0000-0002-8470-1247
Haowen JiangDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China. haowj_sh@fudan.edu.cn.ORCID http://orcid.org/0000-0002-5349-1363
Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical significance and immune correlation of CD103

methodsIn total, 1080 patients with PCa underwent radical prostatectomy from three cohorts were enrolled for retrospective analysis. Tumour microarrays were constructed and fresh tumour samples were analysed by flow cytometry.

resultsHigh CD103 DISCUSSION: CD103

Indexed as

CD8-Positive T-LymphocytesProstatic NeoplasmsAntigens, CDHumansIntegrin alpha ChainsLymphocytes, Tumor-InfiltratingMalePrevalencePrognosisRetrospective Studiesalpha E integrinsAntigens, CDIntegrin alpha Chains

Identifiers

PMID36759726
PMCPMC10070496
OpenAlexW4319662762

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.